222 related articles for article (PubMed ID: 8817830)
21. Mosquito Infectivity and Parasitemia after Controlled Human Malaria Infection.
Walk J; van Gemert GJ; Graumans W; Sauerwein RW; Bijker EM
Am J Trop Med Hyg; 2018 Jun; 98(6):1705-1708. PubMed ID: 29714158
[TBL] [Abstract][Full Text] [Related]
22. Plasmodium falciparum: administration of anti-sporozoite antibodies during sporogony results in production of sporozoites which are not neutralized by human anti-circumsporozoite protein vaccine sera.
do Rosario VE; Appiah A; Vaughan JA; Hollingdale MR
Trans R Soc Trop Med Hyg; 1989; 83(3):305-7. PubMed ID: 2694460
[TBL] [Abstract][Full Text] [Related]
23. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
Cummings JF; Spring MD; Schwenk RJ; Ockenhouse CF; Kester KE; Polhemus ME; Walsh DS; Yoon IK; Prosperi C; Juompan LY; Lanar DE; Krzych U; Hall BT; Ware LA; Stewart VA; Williams J; Dowler M; Nielsen RK; Hillier CJ; Giersing BK; Dubovsky F; Malkin E; Tucker K; Dubois MC; Cohen JD; Ballou WR; Heppner DG
Vaccine; 2010 Jul; 28(31):5135-44. PubMed ID: 19737527
[TBL] [Abstract][Full Text] [Related]
24. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults.
Moorthy VS; Imoukhuede EB; Milligan P; Bojang K; Keating S; Kaye P; Pinder M; Gilbert SC; Walraven G; Greenwood BM; Hill AS
PLoS Med; 2004 Nov; 1(2):e33. PubMed ID: 15526058
[TBL] [Abstract][Full Text] [Related]
25. Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein.
Persson C; Oliveira GA; Sultan AA; Bhanot P; Nussenzweig V; Nardin E
J Immunol; 2002 Dec; 169(12):6681-5. PubMed ID: 12471098
[TBL] [Abstract][Full Text] [Related]
26. Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi.
Pirahmadi S; Zakeri S; A Mehrizi A; D Djadid N; Raz AA; J Sani J; Abbasi R; Ghorbanzadeh Z
Malar J; 2019 Apr; 18(1):146. PubMed ID: 31014347
[TBL] [Abstract][Full Text] [Related]
27. Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA.
Richie TL; Charoenvit Y; Wang R; Epstein JE; Hedstrom RC; Kumar S; Luke TC; Freilich DA; Aguiar JC; Sacci JB; Sedegah M; Nosek RA; De La Vega P; Berzins MP; Majam VF; Abot EN; Ganeshan H; Richie NO; Banania JG; Baraceros MF; Geter TG; Mere R; Bebris L; Limbach K; Hickey BW; Lanar DE; Ng J; Shi M; Hobart PM; Norman JA; Soisson LA; Hollingdale MR; Rogers WO; Doolan DL; Hoffman SL
Hum Vaccin Immunother; 2012 Nov; 8(11):1564-84. PubMed ID: 23151451
[TBL] [Abstract][Full Text] [Related]
28. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S
PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487
[TBL] [Abstract][Full Text] [Related]
29. The Delay in the Licensing of Protozoal Vaccines: A Comparative History.
Palatnik-de-Sousa CB; Nico D
Front Immunol; 2020; 11():204. PubMed ID: 32210953
[TBL] [Abstract][Full Text] [Related]
30. Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A.
Fries LF; Gordon DM; Schneider I; Beier JC; Long GW; Gross M; Que JU; Cryz SJ; Sadoff JC
Infect Immun; 1992 May; 60(5):1834-9. PubMed ID: 1563771
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
32. Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial.
Aide P; Dobaño C; Sacarlal J; Aponte JJ; Mandomando I; Guinovart C; Bassat Q; Renom M; Puyol L; Macete E; Herreros E; Leach A; Dubois MC; Demoitie MA; Lievens M; Vekemans J; Loucq C; Ballou WR; Cohen J; Alonso PL
Vaccine; 2011 Aug; 29(35):6059-67. PubMed ID: 21443960
[TBL] [Abstract][Full Text] [Related]
33. Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum.
Genton B; D'Acremont V; Lurati-Ruiz F; Verhage D; Audran R; Hermsen C; Wolters L; Reymond C; Spertini F; Sauerwein R
Vaccine; 2010 Sep; 28(40):6573-80. PubMed ID: 20691266
[TBL] [Abstract][Full Text] [Related]
34. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.
Stoute JA; Slaoui M; Heppner DG; Momin P; Kester KE; Desmons P; Wellde BT; Garçon N; Krzych U; Marchand M
N Engl J Med; 1997 Jan; 336(2):86-91. PubMed ID: 8988885
[TBL] [Abstract][Full Text] [Related]
35. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types.
Nardin EH; Calvo-Calle JM; Oliveira GA; Nussenzweig RS; Schneider M; Tiercy JM; Loutan L; Hochstrasser D; Rose K
J Immunol; 2001 Jan; 166(1):481-9. PubMed ID: 11123327
[TBL] [Abstract][Full Text] [Related]
36. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial.
Thompson FM; Porter DW; Okitsu SL; Westerfeld N; Vogel D; Todryk S; Poulton I; Correa S; Hutchings C; Berthoud T; Dunachie S; Andrews L; Williams JL; Sinden R; Gilbert SC; Pluschke G; Zurbriggen R; Hill AV
PLoS One; 2008 Jan; 3(1):e1493. PubMed ID: 18231580
[TBL] [Abstract][Full Text] [Related]
37. Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial.
Sulyok Z; Fendel R; Eder B; Lorenz FR; Kc N; Karnahl M; Lalremruata A; Nguyen TT; Held J; Adjadi FAC; Klockenbring T; Flügge J; Woldearegai TG; Lamsfus Calle C; Ibáñez J; Rodi M; Egger-Adam D; Kreidenweiss A; Köhler C; Esen M; Sulyok M; Manoj A; Richie TL; Sim BKL; Hoffman SL; Mordmüller B; Kremsner PG
Nat Commun; 2021 May; 12(1):2518. PubMed ID: 33947856
[TBL] [Abstract][Full Text] [Related]
38. Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial.
Oneko M; Steinhardt LC; Yego R; Wiegand RE; Swanson PA; Kc N; Akach D; Sang T; Gutman JR; Nzuu EL; Dungani A; Kim Lee Sim B; Oloo PN; Otieno K; Bii DK; Billingsley PF; James ER; Kariuki S; Samuels AM; Jongo S; Chebore W; Abdulla S; Daubenberger C; Mpina M; Styers D; Potter GE; Abarbanell G; Richie TL; Hoffman SL; Seder RA
Nat Med; 2021 Sep; 27(9):1636-1645. PubMed ID: 34518679
[TBL] [Abstract][Full Text] [Related]
39. Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial.
Walk J; Reuling IJ; Behet MC; Meerstein-Kessel L; Graumans W; van Gemert GJ; Siebelink-Stoter R; van de Vegte-Bolmer M; Janssen T; Teelen K; de Wilt JHW; de Mast Q; van der Ven AJ; Diez Benavente E; Campino S; Clark TG; Huynen MA; Hermsen CC; Bijker EM; Scholzen A; Sauerwein RW
BMC Med; 2017 Sep; 15(1):168. PubMed ID: 28903777
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial.
Alonso PL; Sacarlal J; Aponte JJ; Leach A; Macete E; Milman J; Mandomando I; Spiessens B; Guinovart C; Espasa M; Bassat Q; Aide P; Ofori-Anyinam O; Navia MM; Corachan S; Ceuppens M; Dubois MC; Demoitié MA; Dubovsky F; Menéndez C; Tornieporth N; Ballou WR; Thompson R; Cohen J
Lancet; 2004 Oct 16-22; 364(9443):1411-20. PubMed ID: 15488216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
